Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
SAN DIEGO, May 08, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration. More than a dozen posters were presented at the recent American Association of Cancer Research’s (AACR) 2018 meeting and are now available to watch and download, https://www.crownbio.com/posters/
These scientific posters describe innovations in CrownBio’s Internal R&D focusing on preclinical oncology research. The most compelling work is now available on-demand and narrated by CrownBio scientists. The library of poster presentations includes details on the development and application of several innovative humanized models, a new largescale ex vivo PDX drug screening service and a novel IDO1 inhibition assay platform. Collectively, the data demonstrate CrownBio’s unique capacity to enhance knowledge, guide development decisions and advance immunotherapy programs.
“CrownBio is providing unfettered access to CrownBio’s innovative research with scientific colleagues worldwide,” said Dr. Henry Li, CrownBio’s Vice President of Translational Oncology. “We are committed to sharing with scientists globally the cutting-edge tools that are available to accelerate, inform and enlighten contemporary evaluation of cancer therapies and immunotherapies.”
“Crown Bioscience is committed to making valuable contributions to the scientific community,” said Dr. Jean Pierre Wery, Crown Bioscience’s Chief Executive Officer. “By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs.”
The library of narrated posters can be found on Crown Bioscience’s website, https://www.crownbio.com/posters/
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
